Ed Zhang is founding CEO of Overland Therapeutics. Immediately prior to Overland Therapeutics, Ed co-foundered its predecessor, Overland Pharma when he was a venture partner at Hillhouse Investment in 2020 and has served as CEO since 2022.

​

Ed brings over 20 years of biopharma industry experience, crossing scientific research, business development, strategy and general management. Before starting at Hillhouse, Ed was VP Corporate Development at Boston Pharmaceuticals as part of its initial founding team, leading corporate development and strategic initiatives. Prior to joining Boston Pharma, Ed headed global business development at Sanofi’s Specialty Products BU and was Director of Strategic Development at Genzyme before its acquisition by Sanofi. He started his career as a medicinal chemist at Pharmacia & Upjohn.

​

Ed holds B.S. from Nanjing University and M.B.A. from Kellogg School of Management at Northwestern University.